Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)

The purpose of this study is to evaluate the treatment outcomes and safety of neoadjuvant therapy including pembrolizumab in real-world practice for patients with triple-negative breast cancer (TNBC) in a multi-center study in Korea. In particular, we aim to evaluate the treatment efficacy focusing on the pathologic complete response (pCR) and analyze the association with recurrence rates and survival indicators.

Participants needed: 2,000
Trial details
Biological sex: AllType: ObservationalSponsor: Yeon Hee ParkUpdated: Sep 18, 2026
Eligibility criteria

Age of 19 years or older at the start of treatment [+2]

History of other invasive malignancies, either concurrently or in the past (exce... [+1]

Read more
Status: Not yet recruiting

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment

Participants needed: 272
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Yeon Hee ParkUpdated: Dec 24, 2025
Eligibility criteria

Participants must be at least 19 years of age at the time of signing the informe... [+18]

Patients whose cancer recurs one year or later after completing adjuvant endocri... [+29]

Read more
Status: Recruiting

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients with metastatic Triple Nagative Breast Cancer who have received at least one, and no more than two, prior standard of care chemotherapy regimens

Participants needed: 40
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Yeon Hee ParkUpdated: Aug 28, 2025Locations: 1
Eligibility criteria

Signed Informed Consent Form (ICF) prior to participation in any study-related a... [+23]

Prior treatment with topoisomerase 1 inhibitors as a free form or as other formu... [+18]

Read more